Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

72.91 +0.44 (+0.61%)

Streaming Delayed Price Updated: 3:11 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

February 26, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

February 24, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

February 20, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

February 13, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

February 11, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Top 4 Health Care Stocks You May Want To Dump In Q1 ↗

January 21, 2025

Via Benzinga

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

BridgeBio Pharma Stock Earns 87 RS Rating ↗

January 14, 2025

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.

Via Investor's Business Daily

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗

January 13, 2025

Some companies saw their shares skyrocket on preliminary reports, but others took hits.

Via Investor's Business Daily

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

January 13, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

January 08, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

December 13, 2024

From BridgeBio Pharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 25, 2024

Via Benzinga

Gold Down Over 3%; Rigetti Computing Shares Spike Higher ↗

November 25, 2024

Via Benzinga

Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October ↗

November 25, 2024

Via Benzinga

Topics Economy

BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday ↗

November 25, 2024

Via Benzinga

BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug ↗

November 25, 2024

BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel.

Via Investor's Business Daily

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market ↗

November 25, 2024

FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality.

Via Benzinga

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

November 22, 2024

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market ↗

November 19, 2024

BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies.

Via Benzinga

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

November 18, 2024

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

November 18, 2024

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

November 12, 2024

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

November 05, 2024

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

October 24, 2024

From BridgeBio Pharma, Inc.

Via GlobeNewswire

3 Top Stocks That Could Still Rocket Higher in 2024 ↗

October 04, 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

Via The Motley Fool

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

October 03, 2024

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease ↗

September 30, 2024

BridgeBio Pharma shared new data showing that acoramidis reduced mortality and cardiovascular hospitalizations by 42% in its Phase 3 ATTRibute-CM study for ATTR-CM. FDA decision expected in November...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.